Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis

Table 1 Characteristics of studies included in the meta-analysis

Ref.	Study type	Follow-up periods	Group	Drug	Drug dosage	Number of cases	Age, yr	Male
Feaganet al[14], 2005	RCT	6 wk	Intervention 1	MLN-02	0.5 mg/kg	58	41.6 ± 14.7	56.9%
			Intervention 2		2 mg/kg	60	43.8 ± 14.6	50.0%
			Control	Placebo	NA	63	38.9 ± 13.4	55.6%
Feagan et al[15], 2013	Randomized allocation	6 wk	Intervention	Vedolizumab	300 mg	746	40.1 ± 13.2	58.0%
			Control	Placebo	NA	149	41.1 ± 1.25	61.7%
Parikh et al[16], 2012	RCT	43 d	Intervention 1	Vedolizumab	2 mg/kg	12	39 (30-49)1	33.3%
			Intervention 2		6 mg/kg	14	47 (19-61)1	50.0%
			Intervention 3		10 mg/kg	11	41 (26-69)1	45.5%
			Control	Placebo	NA	9	33 (21-51)1	33.3%

¹Median (range). RCT: Randomized controlled trial; NA: No data available.